Glasgow

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• High blood pressure4 trials
• Alzheimer disease1 trial
• Chronic kidney disease1 trial
• Huntington's disease1 trial
• Lichen planus1 trial

Phase

• Phase 24 trials
• Phase 12 trials
• Phase 2/31 trial
• Phase 31 trial

Status

• Recruiting4 trials
• Completed3 trials
• Active, not recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals7 trials
• Priovant Therapeutics, Inc.1 trial

Running trials

• Recruiting

  A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

  NCT07532603· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Recruiting

  A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

  NCT07214727· Phase 1· Alnylam Pharmaceuticals· Source

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

  NCT06585449· Phase 1· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Lichen planus1 recruiting

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Alnylam Pharmaceuticals· Source